Welcome to AIDS PATIENT CARE AND STDS, a leading journal dedicated to the comprehensive exploration of clinical practices, research advancements, and public health strategies centered around HIV/AIDS and sexually transmitted diseases. Published by Mary Ann Liebert, Inc., this esteemed journal has been at the forefront of disseminating critical findings since 1996, contributing to a robust understanding of the complexities surrounding these global health issues. With an impressive impact factor reflected in its 2023 Q1 quartile rankings in both Infectious Diseases and Public Health, Environmental and Occupational Health, the journal stands out among its peers, ranking at the 95th percentile for Public Health and 91st percentile in Infectious Diseases. Researchers, healthcare professionals, and students will benefit from its rich content, comprehensive studies, and critical reviews that aim to improve care practices and health outcomes. With a clear commitment to fostering knowledge and collaboration in the field, AIDS PATIENT CARE AND STDS is an essential resource for those dedicated to combating these pressing health challenges.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a leading peer-reviewed journal dedicated to advancing the field of infectious diseases, particularly focusing on tuberculosis and other mycobacterial infections. Published by ELSEVIER in the United Kingdom with an impressive open access model since 2015, this journal aims to provide a platform for the dissemination of high-quality research, clinical findings, and innovative methodologies in the management of mycobacterial diseases. With a commendable impact, the journal currently holds a Q2 ranking in multiple categories including Infectious Diseases and Pulmonary and Respiratory Medicine, reflecting its influence in the academic community. The journal is dedicated to serving researchers, healthcare professionals, and students by offering access to essential information that can improve patient outcomes and enhance public health strategies. As the field of mycobacterial diseases continues to evolve, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases remains a crucial resource for those seeking to remain at the forefront of research and clinical practice.

JOURNAL OF INFECTION is a premier academic publication in the fields of infectious diseases and medical microbiology, published by W B SAUNDERS CO LTD. With a profound impact factor and established since 1979, this journal serves as a crucial resource for researchers, clinicians, and policy-makers seeking to advance knowledge and understanding of infectious processes and their management. The JOURNAL OF INFECTION holds an impressive position in the academic hierarchy as reflected by its Q1 quartile rankings in both Infectious Diseases and Microbiology (medical) for 2023, further underscored by its Scopus rankings: #2 in Medical Microbiology and #5 in Medical Infectious Diseases, placing it in the 98th percentile overall. While the journal does not offer Open Access options, it provides a comprehensive outlet for innovative research, reviews, and clinical insights that drive the field forward. Published from the United Kingdom, it attracts a global readership keen on staying at the forefront of infectious disease research, making it an essential addition to any academic and clinical library.

AIDS Research and Treatment is a premier open access journal published by HINDAWI LTD, dedicated to advancing the understanding and treatment of HIV/AIDS and related conditions. Launched in 2010, the journal has established itself as a vital resource for researchers, healthcare professionals, and students in the fields of Dermatology, Immunology, Infectious Diseases, and Public Health. With a notable 2023 impact factor reflected in its Q2 and Q3 quartile rankings across key medical categories, the journal plays a critical role in disseminating high-quality research and fostering innovation in the prevention and treatment of AIDS. It provides a wide range of open access options, enabling easier dissemination and increased visibility of research findings globally. As the landscape of HIV/AIDS research continues to evolve, AIDS Research and Treatment remains at the forefront, ensuring crucial insights and developments are shared to enhance public health outcomes.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA is a prominent journal dedicated to the fields of infectious diseases and clinical microbiology, published by EDICIONES DOYMA S A in Spain. With an ISSN of 0213-005X and an e-ISSN of 1578-1852, the journal has been a cornerstone of research and scholarly communication since its inception in 1989. As of 2023, it holds a Q3 category ranking in Infectious Diseases, highlighting its significance in the field, alongside a Q4 ranking in the related area of Microbiology. Although the journal is not open access, it remains an essential resource for professionals, researchers, and students aiming to stay informed on advancements and studies that impact clinical practices in infectious diseases. With Scopus ranks indicating a percentile ranking in the 20th to 34th range across various sub-disciplines, ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA continually contributes to the dialogue and development of science, fostering a deeper understanding of complex microbial interactions and disease mechanisms.

HIV Medicine is a prestigious journal published by Wiley that stands at the forefront of research in the fields of health policy, infectious diseases, and pharmacology, with a commendable impact factor reflected in its Q1 rankings for 2023. Established in 1999 and set to converge its expertise through 2024, this journal plays a critical role in advancing the understanding and treatment of HIV and related health challenges. It is esteemed for its rigorous peer-review process and its contributions to both clinical and policy-oriented discussions surrounding HIV medicine. With a broad international readership, it serves as a vital resource for researchers, healthcare professionals, and students committed to fighting the global HIV epidemic. Although not open access, its vital insights are indispensable for anyone involved in infectious disease research and healthcare policy. Articles published in HIV Medicine shape global health strategies and influence the future of HIV research, making it a must-read for those dedicated to this crucial field.

VIROLOGIE is a prominent international journal dedicated to advancing the field of virology and infectious diseases, published by John Libbey Eurotext Ltd. Since its inception in 1997, this journal has provided a platform for researchers and professionals to disseminate their findings on various aspects of virology, including the pathogenesis, epidemiology, and treatment of viral infections. Despite its current ranking in Q4 for both Infectious Diseases and Virology categories, the journal remains a valuable resource for emerging research and novel insights. The ISSN for the journal is 1267-8694, and it is based in France. VIROLOGIE is committed to upholding rigorous academic standards and fosters an inclusive scholarly community, making it an essential read for those pursuing knowledge and advancements in the ever-evolving landscape of virology. While the journal does not currently offer open access options, it continues to contribute significantly to the global discourse on viral research through its diverse range of published studies.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.